Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

NCT Number	NCT07181109
Lead Sponsor	Alnylam Pharmaceuticals Collaborators: Hoffmann-La Roche
Conditions	High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Enrollment	11,000 participants
Start Date	2025-09-22
Primary Completion	2030-09-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-13